Ligand Pharmaceuticals (LGND) Other Gross PP&E Adjustments: 2011-2025
Historic Other Gross PP&E Adjustments for Ligand Pharmaceuticals (LGND) over the last 11 years, with Sep 2025 value amounting to -$7.6 million.
- Ligand Pharmaceuticals' Other Gross PP&E Adjustments fell 6.32% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 11.03%. This contributed to the annual value of $8.9 million for FY2024, which is 35.75% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Other Gross PP&E Adjustments of -$7.6 million as of Q3 2025, which was up 4.78% from -$8.0 million recorded in Q2 2025.
- In the past 5 years, Ligand Pharmaceuticals' Other Gross PP&E Adjustments registered a high of $17.9 million during Q4 2022, and its lowest value of -$32.1 million during Q3 2022.
- For the 3-year period, Ligand Pharmaceuticals' Other Gross PP&E Adjustments averaged around -$4.0 million, with its median value being -$7.2 million (2024).
- The largest annual percentage gain for Ligand Pharmaceuticals' Other Gross PP&E Adjustments in the last 5 years was 293.79% (2021), contrasted with its biggest fall of 293.42% (2021).
- Ligand Pharmaceuticals' Other Gross PP&E Adjustments (Quarterly) stood at $11.0 million in 2021, then soared by 63.51% to $17.9 million in 2022, then dropped by 23.06% to $13.8 million in 2023, then crashed by 35.75% to $8.9 million in 2024, then fell by 6.32% to -$7.6 million in 2025.
- Its Other Gross PP&E Adjustments was -$7.6 million in Q3 2025, compared to -$8.0 million in Q2 2025 and -$800,000 in Q1 2025.